Melatonergic drugs in development
Alessia Carocci,1 Alessia Catalano,1 Maria Stefania Sinicropi2 1Department of Pharmacy–Drug Sciences, University of Bari Aldo Moro, Bari, 2Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Cosenza, Italy Abstract: Melatonin (N-acetyl-5-methoxytryptamine) is...
Guardado en:
Autores principales: | Carocci A, Catalano A, Sinicropi MS |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9fe6719d7e3b447d8546a22f3a69f4bc |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Scientific and regulatory evaluation of mechanistic in silico drug and disease models in drug development: Building model credibility
por: Flora T. Musuamba, et al.
Publicado: (2021) -
A framework to guide dose & regimen strategy for clinical drug development
por: Oliver Sander, et al.
Publicado: (2021) -
Development of physiologically‐based pharmacokinetic models for standard of care and newer tuberculosis drugs
por: Helen Humphries, et al.
Publicado: (2021) -
Cross‐company collaboration to leverage analytics for clinical quality and accelerate drug development: The IMPALA industry group
por: Timothé Ménard, et al.
Publicado: (2021) -
Drug-resistant tuberculosis: emerging treatment options
por: Adhvaryu MR, et al.
Publicado: (2011)